Table 1. Characteristics of patients offering lung tissues.

C, control tissue; P, patient tissue; aPAH, associated PAH (collagen vascular disease); CTEPH, chronic thromboembolic pulmonary hypertension; PDE5i, phosphodiesterase type 5 inhibitor; ERA, endothelin receptor antagonist; Prostn, parenteral prostanoid; sGC, soluble guanylate cyclase; WHO, World Health Organization.

	Patient	Diagnosis	Age	Sex	WHO class	PAH therapy
Histology/immunoblots	C1	Lobectomy (tumor)	56	M	II	None
	C2	Unused transplant donor	25	M	I	None
	C3	Unused transplant donor	38	F	I	None
	C4	Unused transplant donor	41	F	I	None
	P1	aPAH	34	F	III	PDE5i + ERA
	P2	iPAH	18	M	IV	PDE5i + Prostn
	P3	iPAH	39	F	IV	ERA + Prostn
	P4	iPAH	31	F	III	ERA + Prostn
	P5	iPAH	42	F	III	PDE5i + ERA + Prostn
	P6	aPAH	40	M	IV	PDE5i + ERA + Prostn	SIRT3 variant	UCP2 variant
EVLP lung	1	aPAH	62	F	IV	PDE5i + ERA + Prostn	G/G	A/A
	2	aPAH	61	F	IV	PDE5i + ERA + Prostn	G/A	A/A
	3	iPAH	32	F	IV	PDE5i + ERA + Prostn	G/G	A/A
	4	iPAH	43	F	IV	PDE5i + ERA + Prostn	G/A	G/G
	5	CTEPH	60	M	IV	sGC stim + Prostn	G/A	A/A